01:51 PM EDT, 03/26/2024 (MT Newswires) -- Mesoblast (MESO) said late Monday it was informed by the US Food and Drug Administration that clinical data from a phase 3 study would be enough to support a proposed biologics license application for remestemcel-L, the company's drug candidate for children with steroid-refractory acute graft versus host disease.

Shares climbed 65% as intraday trading volume shot to more than 57 million from a daily average of about 407,000.

Stoke Therapeutics ( STOK ) said late Monday it unveiled "landmark" new data supporting the potential for STK-001 to be the first disease-modifying medicine to treat patients with Dravet syndrome.

Shares soared 72% as intraday trading volume jumped to over 16.8 million from a daily average of roughly 258,000.

McCormick's ( MKC ) shares advanced more than 10% after the company's fiscal Q1 adjusted earnings and net sales reported Tuesday beat market expectations.

More than 4 million shares traded intraday compared with a daily average of about 2 million.

Price: 3.63, Change: +1.43, Percent Change: +65.04